Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti
C M
CM
University of Texas Health Science Center, San Antonio.
LeMaistre
C F
CF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004167:Diphtheria Toxin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D000922:Immunotoxins; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins